(("coronary arter*" adj3 occlusion) or (heart adj2 (infarct* or necrosis)) or "cardiac infarct*" or "cardial infarct*" or "cardiogenic shock" or "dressler syndrome" or "heart attack*" or "myocardial infarct*" or "myocardial stunning" or "myocardium infarct*" or "premonitory infarction sign" or "subendocardial infarct*").ti,ab,hw,kw. 606258 4 1 or 2 or 3 608529 5 acute.ti,ab,hw,kw. and 4 239685 6 exp Heart Failure/ 498877 7 (((heart or cardiac or myocardial) adj2 (failure or decompensat* or insufficienc* or incompetence)) or "cardio-renal syndrome*" or "cardiorenal syndrome*" or "paroxysmal dyspnea*" or "decompensatio cordis" or "insufficientia cardis").ti,ab,hw,kw. 519250 8 6 or 7 633042 9 exp Pneumonia/ 313860 10 ("acute chest syndrome" or Bronchopneumonia* or "inflammatory lung disease*" or lobitis or "lung inflammation*" or pleuropneumonia* or pleuropneumonitis or "pneumonia pleuritica" or "pneumonia superficialis" or pneumonia* or "pneumonic lung*" or "pneumonic pleurisy" or "pneumonic pleuritis" or pneumonitides or pneumonitis or "pulmonal inflammation*" or "pulmonary inflammation*" or "pulmonic inflammation*").ti,ab,hw,kw. 533949 11 9 or 10 549542 12 5 or 8 or 11 1350218 13 exp Hyperlipidemias/ 192450 14 ("Buerger Gruetz syndrome" or "Burger Grutz syndrome" or cholesteremia* or cholesterinemia* or cholesterolemia* or "familial hyperbetalipoproteinaemia*" or "familial hyperbetalipoproteinemia*" or "familial hypercholesterolemic xanthomatos*" or "familial hyperlipoproteinaemia type ii" or "familial hyperlipoproteinemia type ii" or "harbitz mueller syndrome" or "hyper low density lipoproteinaemia*" or "hyper low density lipoproteinemia*" or hyperbetalipoproteinaemia* or hyperbetalipoproteinemia* or hypercholesteremia* or hypercholesterinaemia* or hypercholesterinemia* or hypercholesterolaemia* or "hypercholesterolaemic xanthomatos*" or hypercholesterolemia* or "hypercholesterolemic xanthomatos*" or hyperlipaemia* or hyperlipemia* or hyperlipidaemia* or hyperlipidemia* or hyperlipidemic or hyperlipoproteinaemia* or hyperlipoproteinemia* or hypertriglyceridaemia* or hypertriglyceridemia* or "hypertriglyceridemic waist" or "ldl receptor disorder" or lipaemia* or lipemia* or lipidaemia* or lipidemia* or "lipoid gout" or "mckusick 14389" or "mckusick 14430" or "mckusick 14440" or "mckusick 14575" or "tendinous xanthogranulomatos*" or "tendinous xanthomatos*" or "tendon xanthogranulomatos*" or "triglyceride storage disease" or triglyceridemia* or "xanthogranulomatosis tendinosum" or "xanthogranulomatosis tendinous" or "xanthoma tendinosum" or "xanthoma tuberosum" or "xanthoma tuberosum multiplex").ti,ab,hw,kw. 15 exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu, dt 80348 16 (Atorvastatin* or bervastatin* or cerivastatin* or compactin* or crilvastatin* or dalvastatin* or fluindostatin* or glenvastatin* or "HMG CoA reductase inhibitor" or "hmg coenzyme a reductase inhibitor" or "hmg-coa reductase inhibitor" or "hydroxymethylglutaryl coa reductase inhibitor" or "hydroxymethylglutaryl coenzyme A reductase inhibitor" or "hydroxymethylglutaryl-coa inhibitor" or "hydroxymethylglutaryl-coa reductase inhibitor" or "hydroxymethylglutarylcoenzyme a inhibitor" or Lovastatin* or Meglutol or mevinolin* or "mevinolinic acid" or "monacolin J" or "monacolin L" or pitavastatin* or Pravastatin* or rosuvastatin* or Simvastatin* or statin* or statins or tenivastatin* or vastatin* ((alpaca or alpacas or amphibian or amphibians or animal or animals or antelope or armadillo or armadillos or avian or baboon or baboons or beagle or beagles or bee or bees or bird or birds or bison or bovine or buffalo or buffaloes or buffalos or "c elegans" or "Caenorhabditis elegans" or camel or camels or canine or canines or carp or cats or cattle or chick or chicken or chickens or chicks or chimp or chimpanze or chimpanzees or chimps or cow or cows or "D melanogaster" or "dairy calf" or "dairy calves" or deer or dog or dogs or donkey or donkeys or drosophila or "Drosophila melanogaster" or duck or duckling or ducklings or ducks or equid or equids or equine or equines or feline or felines or ferret or ferrets or finch or finches or fish or flatworm or flatworms or fox or foxes or frog or frogs or "fruit flies" or "fruit fly" or "G mellonella" or "Galleria mellonella" or geese or gerbil or gerbils or goat or goats or goose or gorilla or gorillas or hamster or hamsters or hare or hares or heifer or heifers or horse or horses or insect or insects or jellyfish or kangaroo or kangaroos or kitten or kittens or lagomorph or lagomorphs or lamb or lambs or llama or llamas or macaque or macaques or macaw or macaws or marmoset or marmosets or mice or minipig or minipigs or mink or minks or monkey or monkeys or mouse or mule or mules or nematode or nematodes or octopus or octopuses or orangutan or "orang-utan" or orangutans or "orang-utans" or oxen or parrot or parrots or pig or pigeon or pigeons or piglet or piglets or pigs or porcine or primate or primates or quail or rabbit or rabbits or rat or rats or reptile or reptiles or rodent or rodents or ruminant or ruminants or salmon or sheep or shrimp or slug or slugs or swine or tamarin or tamarins or toad or toads or trout or urchin or urchins or vole or voles or waxworm or waxworms or worm or worms or xenopus or "zebra fish" or zebrafish) not (human or humans or patient or patients)).ti,ab,hw,kw. 7727415 31 28 not (29 or 30) 23991 4 32 limit 31 to english language 22671 33 limit 32 to (conference abstract or editorial or erratum or note or addresses or autobiography or bibliography or biography or blogs or comment or dictionary or directory or interactive tutorial or interview or lectures or legal cases or legislation or news or newspaper article or overall or patient education handout or periodical index or portraits or published erratum or video-audio media or webcasts) [ ((control* adj3 study) or (control* adj3 trial) or (randomized adj3 study) or (randomized adj3 trial) or (randomised adj3 study) or (randomised adj3 trial) or "pragmatic clinical trial" or (random* adj1 allocat*) or (doubl* adj blind*) or (doubl* adj mask*) or (singl* adj blind*) or (singl* adj mask*) or (tripl* adj blind*) or (tripl* adj mask*) or (trebl* adj blind*) or (trebl* adj mask*) or "latin square" or placebo* or nocebo* or multivariate or "comparative study" or "comparative survey" or "comparative analysis" or (intervention* adj2 study) or (intervention* adj2 trial) or "cross-sectional study" or "cross-sectional analysis" or "cross-sectional survey" or "cross-sectional design" or "prevalence study" or "prevalence analysis" or "prevalence survey" or "disease frequency study" or "disease frequency analysis" or "disease frequency survey" or crossover or "cross-over" or cohort* or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or "longitudinal evaluation" or longitudinal* or ((retrospective or "ex post facto") adj3 (study or survey or analysis or design)) or retrospectiv* or "prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "concurrent study" or "concurrent survey" or "concurrent analysis" or "clinical study" or "clinical trial" or "case control study" or "case base study" or "case referrent study" or "case referent study" or "case referent study" or 5 "case compeer study" or "case comparison study" or "matched case control" or "multicenter study" or "multi-center study" or "odds ratio" or "confidence interval" or "change analysis" or ((study or trial or random* or control*) and compar*)).mp,pt. 57 or/35-56 18453897 58 34 and 57 14467 59 exp *Hyperlipidemias/ or exp *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu, dt or *Dyslipidemias/ or ("Buerger Gruetz syndrome" or "Burger Grutz syndrome" or cholesteremia* or cholesterinemia* or cholesterolemia* or "familial hyperbetalipoproteinaemia*" or "familial hyperbetalipoproteinemia*" or "familial hypercholesterolemic xanthomatos*" or "familial hyperlipoproteinaemia type ii" or "familial hyperlipoproteinemia type ii" or "harbitz mueller syndrome" or "hyper low density lipoproteinaemia*" or "hyper low density lipoproteinemia*" or hyperbetalipoproteinaemia* or hyperbetalipoproteinemia* or hypercholesteremia* or hypercholesterinaemia* or hypercholesterinemia* or hypercholesterolaemia* or "hypercholesterolaemic xanthomatos*" or hypercholesterolemia* or "hypercholesterolemic xanthomatos*" or hyperlipaemia* or hyperlipemia* or hyperlipidaemia* or hyperlipidemia* or hyperlipidemic or hyperlipoproteinaemia* or hyperlipoproteinemia* or hypertriglyceridaemia* or hypertriglyceridemia* or "hypertriglyceridemic waist" or "ldl receptor disorder" or lipaemia* or lipemia* or lipidaemia* or lipidemia* or "lipoid gout" or "mckusick 14389" or "mckusick 14430" or "mckusick 14440" or "mckusick 14575" or "tendinous xanthogranulomatos*" or "tendinous xanthomatos*" or "tendon xanthogranulomatos*" or "triglyceride storage disease" or triglyceridemia* or "xanthogranulomatosis tendinosum" or "xanthogranulomatosis tendinous" or "xanthoma tendinosum" or "xanthoma tuberosum" or "xanthoma tuberosum multiplex" or (Atorvastatin* or bervastatin* or cerivastatin* or compactin* or crilvastatin* or dalvastatin* or fluindostatin* or glenvastatin* or "HMG CoA reductase inhibitor" or "hmg coenzyme a reductase inhibitor" or "hmg-coa reductase inhibitor" or "hydroxymethylglutaryl coa reductase inhibitor" or "hydroxymethylglutaryl coenzyme A reductase inhibitor" or "hydroxymethylglutaryl-coa inhibitor" or "hydroxymethylglutaryl-coa reductase inhibitor" or "hydroxymethylglutarylcoenzyme a inhibitor" or Lovastatin* or Meglutol or mevinolin* or "mevinolinic acid" or "monacolin J" or "monacolin L" or pitavastatin* or Pravastatin* or rosuvastatin* or Simvastatin* or statin* or statins or tenivastatin* or vastatin*) or (dyslipidemia or dyslipoproteinemia)).ti.
170773 60 exp *Myocardial Infarction/ or exp *heart infarction/ or exp *Heart Failure/ or exp *Pneumonia/ or (("coronary arter*" adj3 occlusion) or (heart adj2 (infarct* or necrosis)) or "cardiac infarct*" or "cardial infarct*" or "cardiogenic shock" or "dressler syndrome" or "heart attack*" or "myocardial infarct*" or "myocardial stunning" or "myocardium infarct*" or "premonitory infarction sign" or "subendocardial infarct*" or (((heart or cardiac or myocardial) adj2 (failure or decompensat* or insufficienc* or incompetence)) or "cardio-renal syndrome*" or "cardiorenal syndrome*" or "paroxysmal dyspnea*" or "decompensatio cordis" or "insufficientia cardis") or ("acute chest syndrome" or Bronchopneumonia* or "inflammatory lung disease*" or lobitis or "lung inflammation*" or pleuropneumonia* or pleuropneumonitis or "pneumonia pleuritica" or "pneumonia superficialis" or pneumonia* or "pneumonic lung*" or "pneumonic pleurisy" or "pneumonic pleuritis" or pneumonitides or pneumonitis or "pulmonal inflammation*" or "pulmonary inflammation*" or "pulmonic inflammation*")).ti. Scopus search strategy 1 TITLE(("coronary arter*" W/3 occlusion) or (heart W/2 (infarct* or necrosis)) or "cardiac infarct*" or "cardial infarct*" or "cardiogenic shock" or "dressler syndrome" or "heart attack*" or "myocardial infarct*" or "myocardial stunning" or "myocardium infarct*" or "premonitory infarction sign" or "subendocardial infarct*") AND TITLE-ABS-KEY(acute) 2 TITLE(((heart or cardiac or myocardial) W/2 (failure or decompensat* or insufficienc* or incompetence)) or "cardio-renal syndrome*" or "cardiorenal syndrome*" or "paroxysmal dyspnea*" or "decompensatio cordis" or "insufficientia cardis") 3 TITLE("acute chest syndrome" or Bronchopneumonia* or "inflammatory lung disease*" or lobitis or "lung inflammation*" or pleuropneumonia* or pleuropneumonitis or "pneumonia pleuritica" or "pneumonia superficialis" or pneumonia* or "pneumonic lung*" or "pneumonic pleurisy" or "pneumonic pleuritis" or pneumonitides or pneumonitis or "pulmonal inflammation*" or "pulmonary inflammation*" or "pulmonic inflammation*") 4 1 or 2 or 3 5
TITLE("Buerger Gruetz syndrome" or "Burger Grutz syndrome" or cholesteremia* or cholesterinemia* or cholesterolemia* or "familial hyperbetalipoproteinaemia*" or "familial hyperbetalipoproteinemia*" or "familial hypercholesterolemic xanthomatos*" or "familial hyperlipoproteinaemia type ii" or "familial hyperlipoproteinemia type ii" or "harbitz mueller syndrome" or "hyper low density lipoproteinaemia*" or "hyper low density lipoproteinemia*" or hyperbetalipoproteinaemia* or hyperbetalipoproteinemia* or hypercholesteremia* or hypercholesterinaemia* or hypercholesterinemia* or hypercholesterolaemia* or "hypercholesterolaemic xanthomatos*" or hypercholesterolemia* or "hypercholesterolemic xanthomatos*" or hyperlipaemia* or hyperlipemia* or hyperlipidaemia* or hyperlipidemia* or hyperlipidemic or hyperlipoproteinaemia* or hyperlipoproteinemia* or hypertriglyceridaemia* or hypertriglyceridemia* or "hypertriglyceridemic waist" or "ldl receptor disorder" or lipaemia* or lipemia* or lipidaemia* or lipidemia* or "lipoid gout" or "mckusick 14389" or "mckusick 14430" or "mckusick 14440" or "mckusick 14575" or "tendinous xanthogranulomatos*" or "tendinous xanthomatos*" or "tendon xanthogranulomatos*" or "triglyceride storage disease" or triglyceridemia* or "xanthogranulomatosis tendinosum" or "xanthogranulomatosis tendinous" or "xanthoma tendinosum" or "xanthoma tuberosum" or "xanthoma tuberosum multiplex") 6 TITLE(Atorvastatin* or bervastatin* or cerivastatin* or compactin* or crilvastatin* or dalvastatin* or fluindostatin* or glenvastatin* or "HMG CoA reductase inhibitor" or "hmg coenzyme a reductase inhibitor" or "hmg-coa reductase inhibitor" or "hydroxymethylglutaryl coa reductase inhibitor" or "hydroxymethylglutaryl coenzyme A reductase inhibitor" or "hydroxymethylglutaryl-coa inhibitor" or "hydroxymethylglutaryl-coa reductase inhibitor" or "hydroxymethylglutaryl-coenzyme a inhibitor" or Lovastatin* or Meglutol or mevinolin* or "mevinolinic acid" or "monacolin J" or "monacolin L" or pitavastatin* or Pravastatin* or rosuvastatin* or Simvastatin* or statin* or statins or tenivastatin* or vastatin*) 7 TITLE(dyslipidemia or dyslipoproteinemia) 8 5 or 6 or 7 9
TITLE-ABS-KEY(surviv* or death* or mortalit* or fatalit*) 10 LANGUAGE(english) 11 TITLE-ABS-KEY((control* W/3 study) or (control* W/3 trial) or (randomized W/3 study) or (randomized W/3 trial) or (randomised W/3 study) or (randomised W/3 trial) or "pragmatic clinical trial" or (random* W/1 allocat*) or (doubl* W/1 blind*) or (doubl* W/1 mask*) or (singl* W/1 blind*) or (singl* W/1 mask*) or (tripl* W/1 blind*) or (tripl* W/1 mask*) or (trebl* W/1 blind*) or (trebl* W/1 mask*) or "latin square" or placebo* or nocebo* or multivariate or "comparative study" or "comparative survey" or "comparative analysis" or (intervention* W/2 study) or (intervention* W/2 trial) or "cross-sectional study" or "cross-sectional analysis" or "cross-sectional survey" or "cross-sectional design" or "prevalence study" or "prevalence analysis" or "prevalence survey" or "disease frequency study" or "disease frequency analysis" or "disease frequency survey" or crossover or "crossover" or cohort* or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or "longitudinal evaluation" or longitudinal* or ((retrospective or "ex post facto") W/3 (study or survey or analysis or design)) or retrospectiv* or "prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "concurrent study" or "concurrent survey" or "concurrent analysis" or "clinical study" or "clinical trial" or "case control study" or "case base study" or "case referrent study" or "case referent study" or "case referent study" or "case compeer study" or "case comparison study" or "matched case control" or "multicenter study" or "multicenter study" or "odds ratio" or "confidence interval" or "change analysis" or ((study or trial or random* or control*) and compar*)) 12 4 and 8 and 9 and 10 and 11 PMID(0*) OR PMID(1*) OR PMID(2*) OR PMID(3*) OR PMID(4*) OR PMID(5*) OR PMID(6*) OR PMID(7*) OR PMID(8*) OR PMID(9*) 18 16 and not 17 19 TITLE(("coronary arter*" W/3 occlusion) or (heart W/2 (infarct* or necrosis)) or "cardiac infarct*" or "cardial infarct*" or "cardiogenic shock" or "dressler syndrome" or "heart attack*" or "myocardial infarct*" or "myocardial stunning" or "myocardium infarct*" or "premonitory infarction sign" or "subendocardial infarct*") AND TITLE-ABS-KEY(acute) 20 18 and 19 21 TITLE(((heart or cardiac or myocardial) W/2 (failure or decompensat* or insufficienc* or incompetence)) or "cardio-renal syndrome*" or "cardiorenal syndrome*" or "paroxysmal dyspnea*" or "decompensatio cordis" or "insufficientia cardis") 22
(18 and not 20) and 21 23
18 and not (20 or 22) SUPPLEMENT 
SUPPLEMENT TABLE 2. Characteristics of studies and participants included in meta-analysis

SUPPLEMENT TABLE 3. Risk of Bias Assessment (Newcastle-Ottawa Scale
NOTE: S1 = Representativeness of the exposed cohort. S2 = Selection of the non-exposed cohort. S3 = Ascertainment of exposure. S4 = Demonstration that the outcome of interest was not present at the start of the study. C1 = Comparability of the cohort on the basis of design. C2 = Comparability of the cohort on the basis of analysis. O1 = Assessment of outcome. O2 = was the follow-up long enough for outcomes to occur? O3 = Adequacy of the follow-up of cohorts.
Selection Compatibility Outcome
Condition
Study
Year S1 S2 S3 S4 C1 C2 O1 O2 O3 Quality 
PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist:
recommended items to address in a systematic review protocol* Title:
Association between hyperlipidemia and mortality after incident acute myocardial infarction or acute decompensated heart failure: A propensity score matched cohort study and a meta-analysis Journal:
BMJ Open
Original title of the manuscript: Hyperlipidemia is associated with lower mortality after incident acute myocardial infarction or acute decompensated heart failure: A propensity matched cohort study and a meta-analysis Describe the mechanism(s) that will be used to manage records and data throughout the review 6, 7 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) 7 through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, 6, 7 in duplicate), any processes for obtaining and confirming data from investigators Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), 7 any pre-planned data assumptions and simplifications Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and 7 additional outcomes, with rationale Risk of bias in individual studies 14
Describe anticipated methods for assessing risk of bias of individual studies, including whether 7 this will be done at the outcome or study level, or both; state how this information will be used in data synthesis Data synthesis 15a
Describe criteria under which study data will be quantitatively synthesised 6, 7 15b If data are appropriate for quantitative synthesis, describe planned summary measures, 6,7 methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I 2 , Kendall's τ) 15c
Describe any proposed additional analyses (such as sensitivity or subgroup a 9 nalyses, meta-regression) 15d
If quantitative synthesis is not appropriate, describe the type of summary planned 9 Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, 6, 7 selective reporting within studies) Confidence in cumulative 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 9 
STROBE Statement
Checklist of items that is included Title:
Association between hyperlipidemia and mortality after incident acute myocardial infarction or acute decompensated heart failure: A propensity score matched cohort study and a meta-analysis Journal: Outcome data 15* Cohort study-Report numbers of outcome events or summary measures over time 9,10 Case-control study-Report numbers in each exposure category, or summary measures of exposure 10 Cross-sectional study-Report numbers of outcome events or summary measures 10
BMJ Open
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 10, 11,12 (b) Report category boundaries when continuous variables were categorized 9, 10 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Other analyses 17 Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses 11, 12
Discussion Key results 18
Summarize key results with reference to study objectives 13
Limitations 19
Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 16 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based 18 *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
